Make a gift before the end of the year to drive research breakthroughs in 2026.
At the Neuroendocrine Tumor Research Foundation (NETRF), we believe that the path to better treatments and cures, starts with research. However, ensuring that we fund
By Anna Greene, PhD, NETRF Director of Research The landscape of biomedical research is undergoing a seismic shift. This year alone, the NIH has awarded
At NETRF, our annual Request for Applications (RFA) is a cornerstone of our mission to fund innovative research in neuroendocrine cancer. This two-stage process is
By Anna Greene, PhD, Director of Research, NETRF Pancreatic neuroendocrine tumors (PanNETs) are a rare but increasingly detected cancer, thanks in part to more widespread
By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs) A study published this month by NETRF-funded Collaborative Grant
Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.
(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the